Meta AnalysisID 4161
静脉铁蔗糖治疗儿童缺铁性贫血的疗效与安全性
CRD42023386858
1. Whether intravenous iron sucrose is efficacious in treating iron deficiency anaemia in children aged up to 14 years? 2. Whether intravenous iron sucrose is efficacious in treating iron deficiency anaemia in children a
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4161
- Evidence Id
- 12719
- Core Evidence Id
- 12719
- Source Meta Analysis Id
- 4120
- Herb2 Meta Analysis Id
- HBMA004120
- Crd Id
- CRD42023386858
- Title
- Efficacy and safety of intravenous iron sucrose for children with iron deficiency
- Review Question
- 1. Whether intravenous iron sucrose is efficacious in treating iron deficiency anaemia in children aged up to 14 years? 2. Whether intravenous iron sucrose is efficacious in treating iron deficiency anaemia in children aged up to 14 years, who failed treatment with oral iron preparations? 3. Whether intravenous iron sucrose is more efficacious in treating iron deficiency anaemia in children aged up to 14 years, as compared to oral iron preparation? 4. What are the adverse effects of intarvenous iron sucrose in children and incidence rate of each of these adverse effects?
- Study Type Included
- Only original articles describing prospective studies, with/without comparison and control arms, enrolling children up to 14 years will be included, only if they have a sample size of 20 or more to provide a true pooled estimate. Small case series, case reports, and retrospective studies were excluded, as also articles describing secondary research like systematic reviews, narrative reviews, brief commentaries, perspectives, editorial communications and scoping reviews, research articles without available full texts, book chapters, conference papers, theses, abstract-only articles, will also be excluded. The studies providing data on efficacy and safety of intravenous iron sucrose therapy only will be included. Studies that did not evaluate these parameters, duplicate/overlapping sample population, non-peer reviewed articles and unreliable data sets will be also excluded.
- Condition Being Studied
- For decades parenteral iron has been used to treat iron deficiency unresponsive to oral iron therapy and hemodialysis-dependent patients receiving erythropoietin. High-molecular weight (HMW) iron dextran, employed extensively in the past, frequently causes anaphylactic reactions, so its use and the use of other parenteral iron preparations in children with hematologic disorders has been very limited. Other iron preparations, including low molecular weight (LMW) iron dextran, iron sucrose, ferric gluconate, and the newest formulation, ferumoxytol, have generally replaced HMW iron dextran for use in both adults and children with chronic kidney disease due to their more favorable safety profiles. Intravenous (IV) iron sucrose was approved by the FDA in 2000 for patients with non-dialysis dependent patients receiving or not receiving erythropoietin therapy and for dialysis dependent chronic kidney disease receiving erythropoietin. Iron sucrose has been reported to be safe and effective in adults with iron deficiency due various non-renal causes, including pregnancy or inflammatory bowel disease. Use of IV iron in children without kidney disease has been explored only in few studies.
- Participant
- Children with confirmed diagnosis of iron deficiency anaemia aged up to 14 years
- Animal
- Human Disease Modelled
- Intervention
- Intravenous iron sucrose therapy at least one dose, irrespective of dose and duration of treatment
- Comparator Control
- Oral iron supplementation, irrespective of the dose and duration of treatment
- Main Outcome
- Change in blood hemoglobin, MCV, serum iron, ferritin, transferrin saturation post-infusion with intravenous iron sucrose as compared to baseline
- Outcome Measure
- Additional Outcome
- Change in blood hemoglobin, MCV, serum iron, ferritin, transferrin saturation between pre-infusion and post-infusion with intravenous iron sucrose and oral iron supplementation group Nature and frequency of each adverse effect with intravenous iron sucrose supplemenattion
- Study Method
- Systematic review
- Keyword
- Anemia, Iron-Deficiency; Child; Ferric Oxide, Saccharated; Humans; Incidence; Iron; Iron Deficiencies
- Contact
- Prateek Kumar Panda [email protected]
- Organisational Affiliation
- AIIMS, Rishikesh
- Funding Source
- Self funded
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- India
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-12-22
- Registration Date
- 2023-01-02
- Anticipated Start Date
- 2023-03-08
- Anticipated Completion Date
- 2023-07-14
- Title Cn
- 静脉铁蔗糖治疗儿童缺铁性贫血的疗效与安全性
- Title En
- Efficacy and safety of intravenous iron sucrose for children with iron deficiency
- Bilingual Status
- complete